Sara Fritzell (Former)
1 – 10 of 17
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
ATOR-4066, a bispecific antibody targeting CD40 and CEACAM5, induces strong myeloid and T cell-dependent tumor immunity and synergizes with PD-1 blockade
(2025) In Cancer immunology research
- Contribution to journal › Article
- 2023
-
Mark
The Bispecific Tumor Antigen-Conditional 4-1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies
- Contribution to journal › Article
- 2021
-
Mark
CD137 (4-1BB) costimulation of CD8+ T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation
- Contribution to journal › Article
- 2020
-
Mark
Education, immigration and rising mental health inequality in Sweden
- Contribution to journal › Article
- 2019
-
Mark
Inequalities in the economic consequences of depression and anxiety in Europe : a systematic scoping review
- Contribution to journal › Article
-
Mark
The effect of locally delivered cisplatin is dependent on an intact immune function in an experimental glioma model
- Contribution to journal › Article
-
Mark
The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation
- Contribution to journal › Article
- 2014
-
Mark
Intratumoral COX-2 inhibition enhances GM-CSF immunotherapy against established mouse GL261 brain tumors.
- Contribution to journal › Article
-
Mark
Immunizations with unmodified tumor cells and simultaneous COX-2 inhibition eradicate malignant rat brain tumors and induce a long-lasting CD8(+) T cell memory.
- Contribution to journal › Article
-
Mark
Intratumorally implanted mesenchymal stromal cells potentiate peripheral immunotherapy against malignant rat gliomas.
- Contribution to journal › Article
